medigraphic.com
Colegio de Medicina Interna de México.

2020, Número 1

<< Anterior Siguiente >>

Med Int Mex 2020; 36 (1)


Posición del Colegio de Medicina Interna de México acerca del nuevo coronavirus, 2019

Márquez-Díaz F, Rojas-Flores DM, Cárdenas-Bravo L, Cadena-Orea D, Pérez-Barragán E, Paredes-Ceballos O, De la Cruz-Hernández I, Cabrera-Rayo A

Idioma: Español
Referencias bibliográficas: 32
Paginas: 87-93
Archivo PDF: 199.93 Kb.


FRAGMENTO

ANTECEDENTES

La existencia de enfermedades emergentes y reemergentes ha generado la alerta de los sistemas de salud mundiales en las últimas décadas con capacidad de ser identificadas, estudiadas y emitir comunicados de información con acciones de respuesta para ellas de manera global.
Los coronavirus son una familia de virus que habitualmente causan infecciones respiratorias leves e intestinales en animales y humanos. Se clasifican en cuatro géneros: alfa, beta, gamma y delta. Los coronavirus humanos (HCoV) se encuentran en dos de estos géneros: alfa-coronavirus y beta-coronavirus. No se consideraron altamente patógenos para los humanos hasta el brote del síndrome respiratorio agudo severo (SRAS) en 2002 y 2003. Años después del síndrome respiratorio agudo severo, otro coronavirus altamente patógeno, el coronavirus del síndrome respiratorio de Oriente Medio (MERS-CoV) surgió en los países de esa región.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019 Mar;17(3):181-192. Doi: 10.1038/s41579-018-0118-9. PMID: 30531947.

  2. Lineamientos estandarizados para la vigilancia epidemiológica y laboratorio de enfermedad por 2019-nCoV, enero 2020.

  3. https://gisanddata.maps.arcgis.com/apps/opsdashboard/ index.html#/bda7594740fd40299423467b48e9ecf6

  4. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020. DOI: 10.1056/NEJMoa2001017.

  5. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020. DOI: https://doi. org/10.1016/S0140-6736(20)30251-8.

  6. National Health Commission of the People’s Republic of China. New coronavirus cases rise to 571 in Chinese mainland. January 23, 2020. http://en.nhc.gov.cn/2020- 01/23/c_76004.htm.

  7. European Centre for Disease Prevention and Control. Novel coronavirus in China. https://www.ecdc.europa.eu/en/ novel-coronavirus-china.

  8. World Health Organization. Novel coronavirus situation report -2. January 22, 2020. https://www.who.int/docs/ default-source/coronaviruse/situation-reports/20200122- sitrep-2-2019-ncov.pdf.

  9. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. DOI: https://doi.org/10.1016/S0140- 6736(20)30183-5.

  10. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13:752-61. doi: 10.1016/S1473-3099(13)70204-4.

  11. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med January 29, 2020. DOI: 10.1056/ NEJMoa2001316.

  12. Chan J, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person to person transmission: a study of a family cluster. Lancet 2020. DOI: https://doi.org/10.1016/S0140- 6736(20)30154-9.

  13. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7.

  14. Comité Nacional para la Vigilancia Epidemiológica. Aviso epidemiológico CONAVE/01/2020/2019-nCoV. Emitido el 21 de enero de 2020.

  15. Instituto de Diagnóstico y Referencia Epidemiológicos Dr. Manuel Martínez Baez. Protocolo de bioseguridad y biocustodia para el manejo de pacientes durante la toma de muestras de casos probables de enfermedad por 2019- nCoV. 2020.

  16. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019- nCoV) infection is suspected. Interim guidance. 28 January 2020. WHO/nCoV/Clinical/2020.2.

  17. Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018;19:81. doi: 10.1186/s13063-017-2427-0.

  18. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9:eaal3653. doi: 10.1126/ scitranslmed.aal3653.

  19. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222. DOI: 10.1038/s41467-019-13940-6.

  20. Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol 2020.

  21. US Centers for Disease Control and Prevention. https:// www.cdc.gov/coronavirus/2019-ncov/about/preventiontreatment. html (accessed Jan 28, 2020).

  22. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020 Jan 24. https://doi.org/10.1016/S0140-6736(20)30185-9.

  23. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: interim guidance, updated October 2019.

  24. CDC: interim guidance for implementing home care of people not requiring hospitalization for 2019 novel coronavirus (2019-nCoV).

  25. World Health Organization; https://www.who.int/dg/ speeches/detail/who-director-general-s-statement-on-ihremergency- committee-on-novel-coronavirus-(2019-ncov). (accessed 31 January 2020).

  26. US Centers for Disease Control and Prevention, https:// wwwnc.cdc.gov/travel/destinations/traveler/none/china (accessed Jan 31, 2020).

  27. WN-CoV. Interim guidance for primary care. BMJ Best Practice. Jan 2020. https://bestpractice.bmj.com/topics/ en-gb/3000165.

  28. US Centers for Disease Control and Prevention, https:// wwwnc.cdc.gov/travel/notices/ warning/novel-coronavirus - china. (accessed Jan 29, 2020).

  29. US Centers for Disease Control and Prevention, https:// www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria. html. (accessed Jan 29, 2020).

  30. Cheng VCC, Chan JFW, To KTW, Yuen KY. Clinical management and infection control of SARS: lessons learned. Antiviral Res 2013;100:407-19. doi: 10.1016/j.antiviral. 2013.08.016.

  31. Fung IC, Cairncross S. Effectiveness of handwashing in preventing SARS: a review. Trop Med Int Health 2006;11:1749- 58. DOI: 10.1111/j.1365-3156.2006.01734.x

  32. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses 2012;4:3044-68. Doi: 10.3390/v4113044.




2020     |     www.medigraphic.com